COMMENTARY: An abnormal D-dimer test result indicated that anticoagulation should be continued
- An abnormal D-dimer test result indicated that anticoagulation should be continued. // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p29
The article cites a research study focusing on the patients with a first episode of venous thromboembolism (VTE), who had received vitamin-K antagonists. An abnormal D-dimer test conducted on these patients indicated that anticoagulation therapy of theses patients should be continued. Patients...
- Aspirin senkt das Risiko eines Thromboembolie-Rezidivs. Mikulicic, Fran // Praxis (16618157);10/17/2012, Vol. 101 Issue 20, p1331
No abstract available.
- Oral Vitamin K for Excessive Anticoagulation. Artz, Andrew S. // Clinical Oncology Alert;Apr2009, Vol. 25 Issue 4, p25
Warfarin is a frequently prescribed oral anticoagulant. The highly variable, dose-response characteristics mandate monitoring, and this is usually accomplished by targeting an international normalized ratio (INR) value between 2.0 to 3.0. Non-therapeutic values are common, and values above 4.5...
- Vitamin K2 May Protect Against Prostate Cancer. Kiefer, Dale // Life Extension;Aug2008, Vol. 14 Issue 8, p24
The article discusses a study which reveals that intakes of vitamins K1 and K2 reduce the risk to develop prostate cancer among men. The study found that men with the highest intakes of vitamin K1 and K2 have the lowest risk of prostate cancer. The study also assessed the effectiveness of...
- D-dimer levels < 250 ng/mL after oral anticoagulation
predicted a low risk for recurrent venous thromboembolism:
COMMENTARY. Kovacs, Michael J. // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p50
The article comments on a study conducted to analyze the association of the levels of D-dimers with the risk of recurrent venous thromboembolism (VTE). Patients with a first episode of unprovoked VTE are at greater risk for recurrence than those who have transient risk factors. The minimum...
- Optimal duration of anticoagulation in patients with venous thromboembolism. Prandoni, Paolo; Piovella, Chiara; Spiezia, Luca; Valle, Fabio Dalla; Pesavento, Raffaele // Indian Journal of Medical Research;Jul2011, Vol. 134 Issue 1, p15
The risk of recurrent venous thromboembolism (VTE) approaches 40 per cent of all patients after 10 yr of follow up. This risk is higher in patients with permanent risk factors of thrombosis such as active cancer, prolonged immobilization from medical diseases, and antiphospholipid syndrome; in...
- Ximelagatran was noninferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation: COMMENTARY. van Walraven, Carl // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p39
The article comments on the study conducted to examine the efficacy of ximelagatran over warfarin in patients with atrial fibrillation (AF) at moderate to high risk for thromboembolic outcomes. From a practical standpoint, ximelagatran is an easier drug to use than warfarin because it can be...
- Using anticoagulants to treat chemotherapy-related VTE. Thompson, Lisa A.; Kim, Miryoung // Oncology Nurse Advisor;May/Jun2012, Vol. 3 Issue 3, p17
No abstract available.
- 45. // Vegetarian Times;Jul/Aug2010, Issue 378, p22
The author reports that a high dietary intake of vitamin K, which is found in leaf lettuce and spinach, may reduce the risk of non-Hodgkin's lymphoma.